Studies have shown that CD44 cleavage is widespread across various malignancies, with ectodomain cleavage detected in 58% of gliomas, 67% of breast carcinomas, 90% of colon carcinomas, and other cancers, including non-small cell lung carcinoma and ovarian carcinoma. Here, CD44 is linked to breast carcinoma.